Certara’s Dr. Fran Brown, SVP Drug Development Science, is featured in this recent Pharmaceutical Executive article on the future for using psychedelic drugs to treat mental health conditions.

Read this article to learn her insights on the FDA’s recent rejection of Lykos’ NDA for MDMA to treat PTSD, the challenges of designing clinical trials for psychedelics, and the changing attitudes of regulators regarding this drug class.